Pharma sector stocks today, September 15: Alembic Pharma jumps 1.58%, Strides Pharma up 0.93%; Divi’s Laboratories falls 1.21%
NiveshIQ
NSE: IPCALAB · Pharma
Ipca Laboratories Ltd.
₹1,968.50▼ ₹2.40 (-0.12%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on IPCALAB. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Ipca Laboratories Ltd.
Ipca Laboratories Limited is an integrated pharmaceutical company that manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, with a revenue of ₹9647 Cr and a net income of ₹1141 Cr. The company's core business is driven by its API offerings in therapeutic areas such as anti-hypertensive, anti-malarial, and diuretic, as well as its generic and branded formulations in segments like allergy, cardiology, and neurology. Recently, the company's shares have jumped 12% to hit a record high on the back of a strong Q1 show, with revised target prices being set by analysts. Ipca Laboratories also exports its products to Europe, Africa, the Americas, and rest of Asia, contributing to its growth. The company's competitive position
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹7,705 Cr +24.20% | ₹8,940 Cr +16.00% | ₹9,646 Cr +7.90% |
| EBITDA Margin | 17.16% | 19.31% | 22.32% |
| Net Profit | ₹522.00 Cr +9.00% | ₹785.00 Cr +50.40% | ₹1,184 Cr +50.80% |
| EPS | ₹21.58 | ₹29.08 | ₹44.98 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
IPCALAB Outlook for the Week (August 31, 2026 – September 04, 2026)
Ipca Laboratories Share Price news on fresh yearly high
🔒
+ 3 more stories about Ipca Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹2, 788 Cr, PAT ₹424 Cr, EPS ₹15.84, EBITDA margin 24.9%. Growth context: revenue QoQ +16.7%, PAT QoQ +38.3%. Street verdict: strong beat, revenue surprise +8.0%, PAT surprise +37.5%.
Key growth drivers for IPCALAB in the near term are expected to be product launches, approvals, and an improvement in th...
In FY26, IPCALAB reported revenue of ₹9, 646 Cr, PAT of ₹1, 184 Cr, an EBITDA margin of 22.3%, and EPS of ₹44.98, repres...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for IPCALAB
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track IPCALAB alongside your other holdings
Unlock full IPCALAB research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Ipca Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Ipca Laboratories Ltd. (IPCALAB) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Ipca Laboratories Ltd.?
Ipca Laboratories Ltd. operates in the Pharma sector with a market capitalisation of ₹4,435,764.8L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.